ASEAN signs GMP inspection agreement

15 April 2009

The Association of Southeast Asian Nations (ASEAN) has signed the ASEAN Sectoral Mutual Recognition Agreement for Good Manufacturing Practice  Inspection of Manufacturers of Medicinal Products, at a summit in  Pattaya, Thailand, shortly before the 14th summit of the regional group  was broken up by local anti-government protesters. The document  highlights the importance of deeper economic integration between the  ASEAN's members with an economic community intended to be realized by  2015.

The Agreement calls for the mutual recognition of GMP certification and  inspection reports by each of the 10 member states' competent  authorities. A statement issued by the ASEAN Secretariat noted that  "these certificates and/or reports will be used as the basis for  regulatory actions such as the granting of approvals or licenses to the  manufacturer, supporting post-market assessments of conformity of these  products and providing information on the manufacturer's facilities  including the testing laboratories, if any, or its contracted  laboratory."

Among the benefits that the regional association hopes to result from  the agreement are: raising the focus of manufacturers on safety and  quality; boosting international recognition of ASEAN members' regulatory  oversight of medicine production; savings to drugmakers by reducing  the duplication of approval procedures from one country to another; and  consumers obtaining the assurance that approved products are safe to  use.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight